Saravanan Raju

Saravanan Raju

Auto-generated profile, based on publicly available information

Saravanan Raju

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
SRSaravanan Raju
Saravanan Raju
LALucas J. Adams
Lucas J. Adams
JEJames T. Earnest
James T. Earnest
KWKelly Warfield
Kelly Warfield
LVLo Vang
Lo Vang
MDMichael Diamond
Michael Diamond
Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes epidemics of acute and chronic musculoskeletal disease. Here, we analyzed the human B cell response to a CHIKV-like particle–adjuvanted vaccine (PXVX0317) from samples obtained from a phase 2 clinical trial in humans (NCT03483961). Immunization with PXVX0317 induced high levels of neutralizing antibody in serum against CHIKV and circulating antigen–specific B cells up to 6 months after immunization. Monoclonal antibodies (mAbs) generated from peripheral blood B cells of three PXVX0317-vaccinated individuals on day 57 after immunization potently neutralized CHIKV infection, and a subset of these inhibited multiple related arthritogenic alphaviruses. Epitope mapping and cryo–electron microscopy defined two broadly neutralizing mAbs that uniquely bind to the apex of the B domain of the E2 glycoprotein. These results demonstrate the inhibitory breadth and activity of the human B cell response induced by the PXVX0317 vaccine against CHIKV and potentially other related alphaviruses.

21 August 2018 in Science Signaling
Verified
Journal Article
Closed access
PDF file
SRSaravanan Raju
Saravanan Raju
DWDaniel M. Whalen
Daniel M. Whalen
MMMeron Mengistu
Meron Mengistu
CSCarter Swanson
Carter Swanson
JQJohn G. Quinn
John G. Quinn
ASAndrey S. Shaw
Andrey S. Shaw
Necroptotic cell death is promoted by the dimerization-dependent activation of the kinase RIPK3.

16 December 2021 in Blood
Verified
Journal Article
Open access
PDF file
ETElena Tonc
Elena Tonc
YTYoshiko Takeuchi
Yoshiko Takeuchi
CCChun Chou
Chun Chou
YXYu Xia
Yu Xia
MHMelanie Holmgren
Melanie Holmgren
TETakeshi Egawa
Takeshi Egawa
The proliferative burst of B lymphocytes is essential for antigen receptor repertoire diversification during the development and selective expansion of antigen-specific clones during immune responses. High proliferative activity inevitably promotes oncogenesis, the risk of which is further elevated in B lymphocytes by endogenous gene rearrangement and somatic mutations. However, B-cell–derived cancers are rare, perhaps owing to putative intrinsic tumor-suppressive mechanisms. We show that c-MYC facilitates B-cell proliferation as a protumorigenic driver and unexpectedly coengages counteracting tumor suppression through its downstream factor TFAP4. TFAP4 is mutated in human lymphoid malignancies, particularly in >10% of Burkitt lymphomas, and reduced TFAP4 expression was associated with poor survival of patients with MYC-high B-cell acute lymphoblastic leukemia. In mice, insufficient TFAP4 expression accelerated c-MYC–driven transformation of B cells. Mechanistically, c-MYC suppresses the stemness of developing B cells by inducing TFAP4 and restricting self-renewal of proliferating B cells. Thus, the pursuant transcription factor cascade functions as a tumor suppressor module that safeguards against the transformation of developing B cells.

25 February 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
SRSaravanan Raju
Saravanan Raju
YXYu Xia
Yu Xia
BDBence Daniel
Bence Daniel
KYKathryn E. Yost
Kathryn E. Yost
EBElliot Bradshaw
Elliot Bradshaw
TETakeshi Egawa
Takeshi Egawa
Persistent antigen induces a dysfunctional CD8 T cell state known as T cell “exhaustion” characterized by expression of PD-1 and decreased effector functions. Nevertheless, dysfunctional CD8 T cells can mediate control of antigen burden which is long-lasting. While heterogeneity of exhausted CD8 T cells has been described, the cells which actively proliferate and exert viral control have remained elusive. Here, we define subsets of PD-1 + CD8 T cells during chronic infection marked by expression of CX3CR1 with substantial in situ proliferation and high expression of granzyme B. Moreover, these cells maintain the effector pool through self-renewal independently of previously defined stem-like cells. Unexpectedly, CX3CR1 + CD8 T cells retain plasticity to be reprogrammed to memory cells through expression of TCF-1 and re-gain polyfunctionality. Thus, we define a subset of effector-like exhausted CD8 T cells with capacity to contribute to the memory pool, offering a prime target for novel immunotherapies.

9 August 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
YXYu Xia
Yu Xia
KSKatalin Sandor
Katalin Sandor
JPJoy A. Pai
Joy A. Pai
BDBence Daniel
Bence Daniel
SRSaravanan Raju
Saravanan Raju
TETakeshi Egawa
Takeshi Egawa
Summary: Shortly after priming, the fate of activated CD4 T cells is segregated into BCL6 + follicular helper T (Tfh) and BCL6 − effector (Teff) cells. However, it remains unknown how these subsets are sustained in the presence of chronic antigen stimulation. Using a combination of single cell- and population-based approaches, we show that in chronic viral infection, activated CD4 T cells differentiate into BCL6-dependent TCF-1 + progenitor cells with superior capacity to expand and give rise to both Teff and Tfh. They share properties with progenitor-exhausted CD8 T cells and are required for the continued generation of Teff cells as antigen persists. In response to tumors, an analogous CD4 T cell population develops in draining lymph nodes. Our study reveals the heterogeneity and plasticity of CD4 T cells upon encountering persistent antigen and highlights their population dynamics through a stable bipotent intermediate state.

8 April 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
SPSathvik Palakurty
Sathvik Palakurty
SRSaravanan Raju
Saravanan Raju
ASAlan Sariol
Alan Sariol
NWNgan Wagoner
Ngan Wagoner
TGTheron C. Gilliland
Theron C. Gilliland
MDMichael Diamond
Michael Diamond
Venezuelan (VEEV), eastern (EEEV), and western (WEEV) equine encephalitis viruses are alphaviruses from different serocomplexes that cause neurological disease in humans. Given their antigenic distance, it has been challenging to isolate cross-reactive antibodies that neutralize infection by multiple medically relevant encephalitic alphaviruses. Recently, distinct entry receptors were identified for these encephalitic alphaviruses: LDLRAD3 for VEEV, VLDLR for EEEV and some strains of WEEV, and PCDH10 for WEEV. Here, using structure-guided mutagenesis, we generated a soluble chimeric protein derived from the LA1 domain of LDLRAD3 and the LA2 domain of VLDLR, termed LDLRAD3-vLA1-VLDLR-LA2, which neutralized infection by VEEV, EEEV, and some WEEV strains in cell culture and protected mice from infection. Structural analysis of this engineered decoy revealed binding to distinct sites on each virus, which corresponded to those engaged by their endogenous entry receptors. We extended the neutralizing and protective capacity to contemporary WEEV strains by adding a single extracellular cadherin domain from sparrow PCDH10 through a stabilized symmetric bispecific decoy scaffold. Our designed receptor decoy serves as a possible countermeasure against multiple encephalitic alphaviruses, and this design platform could be harnessed to develop therapeutic agents against viruses from other families.